About DataMeds AI, Inc. (MEDS) data
Data as of August 14, 2026.
DataMeds AI, Inc. (MEDS) has 164.85K shares sold short as of the latest FINRA settlement report on August 14, 2026. Short interest has increased by 61.57% compared with the prior settlement. At the current average daily volume, covering all open short positions would take about 0.73 days (days to cover).
Recent MEDS short interest history
| Settlement date | Short interest | Change | Days to cover |
|---|---|---|---|
| Aug 14, 2026 | 164,850 | 61.57% | 1.00 |
| Jul 31, 2026 | 102,033 | 46.36% | 1.24 |
| Sep 13, 2024 | 18,221 | 21.47% | 1.20 |
| Aug 30, 2024 | 15,001 | -35.00% | 1.00 |
| Aug 15, 2024 | 23,078 | -46.15% | 1.00 |
| Jul 31, 2024 | 42,856 | 54.27% | 1.00 |
| Jul 15, 2024 | 27,780 | -60.65% | 1.00 |
| Jun 28, 2024 | 70,600 | 921.71% | 1.00 |
| Jun 14, 2024 | 6,910 | -30.73% | 1.45 |
| May 31, 2024 | 9,975 | -6.25% | 1.00 |
| May 15, 2024 | 10,640 | -12.55% | 1.38 |
| Apr 30, 2024 | 12,167 | -40.73% | 1.00 |
Full history, charts, and borrow-fee detail are on the MEDS short interest page.
Frequently asked questions
What is the current short interest in MEDS?
As of the latest FINRA settlement dated August 14, 2026, MEDS had approximately 164,850 shares sold short. Short interest data is reported by FINRA twice per month.
How much does it cost to short MEDS?
The latest borrow fee (cost to borrow) for MEDS is 99.50% per year, based on IBKR data. Fees can change throughout the trading day as shares are borrowed and returned.
What is the days to cover ratio for MEDS?
Days to cover for MEDS is approximately 0.73 days. This estimates how many trading days it would take short sellers to buy back all outstanding short shares at the current average daily volume.
Is MEDS a short squeeze candidate?
A squeeze needs shorts that are hard to close. MEDS trades about 225,774 shares a day and would take roughly 0.73 days to unwind current short positions, at a current borrow fee of 99.50%. Higher days-to-cover and a rising borrow fee together are the setup to watch; neither alone is enough.